ATLANTA and SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) and Kikoff, a personal finance platform that expands access to credit and financial services, today announced that Optimal ...
The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) — Equifax® Canada introduces Optimal Path™, an interactive solution that uses an individual’s credit data to create personalized, actionable suggestions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results